Summary
Attrition in drug discovery and development continues to be a major challenge for the pharmaceutical industry. Bringing a drug from discovery to market is costly and time-consuming, and every drug that fails carries additional cost for the developing company’s reputation and finances.
With an estimated total worldwide R&D spend of $US 141 billion in 2015, large pharmaceutical and biotechnology companies want to ensure that they get an appropriate return on their investment – and that is estimated to require the launch of two to three new chemical or biological drugs by each company annually.
More flexible and science-led approaches to safety assessments incorporating the latest innovations in non-clinical testing are leading to considerable improvements in the ability of safety studies to assess and reduce the risk of subsequent drug failure.
This White Paper Includes:
- Explore how molecule type is driving design of programs and individual safety assessment studies
- Learn how innovations in technology are improving safety assessment data and study outcomes
- Understand how high-risk drugs are being identified earlier in the development process
- Discover the opportunity that improvements in assay techniques bring to translational biomarkers in safety assessment
Click here to view the White Paper
Click here for more information on Envigo